| 发明名称 |
Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders |
| 摘要 |
A montelukast composition having a therapeutically effective amount of montelukast in a sustained release is disclosed. A montelukast composition having a therapeutically effective amount of montelukast in an immediate release and sustained release is also disclosed. |
| 申请公布号 |
US9149472(B2) |
申请公布日期 |
2015.10.06 |
| 申请号 |
US201314071610 |
申请日期 |
2013.11.04 |
| 申请人 |
|
发明人 |
Schultz Jack William |
| 分类号 |
A61K31/47;A61K9/50;A61K45/06;A61K31/198;A61K31/4178;A61K31/519;A61K31/525 |
主分类号 |
A61K31/47 |
| 代理机构 |
Taylor English Duma LLP |
代理人 |
Taylor English Duma LLP |
| 主权项 |
1. A method for improving cognitive function comprising:
selecting a patient, and administering to the patient montelukast sodium in a solid dosage form, the solid dosage form comprising a therapeutically effective amount of montelukast sodium, wherein the amount of montelukast sodium is greater than about 20 mg, and a rate release modifier, wherein the rate release modifier provides the patient a controlled release of montelukast sodium for at least about 4 hours. |
| 地址 |
|
